Skip to Main Content

Paper Details

Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways.
Br J Cancer
27
2020
Author NameAffiliation
Karen MesserUniversity of California San Diego
Peter T SageUniversity of California San Diego
Peter T SagePeckham Center for Cancer and Blood Disorders, Rady Children's Hospital
  • 1 - 3

Datasets

Release 1.2